Parathyroid hormone and related peptides for the treatment of postmenopausal osteoporosis

Bibliography

• BROWN EM: Extracellular Ca2+ sensing, regulation of parathyroid cell function and role of Ca2+ and other ions as extracellular (first) messengers. Physiol. Rev. (1991) 71:371–411.
   PubMed Web of Science ®Google Scholar
• HOUCK MF, KRANE SM, POTTS JT, Jr.: Disorders of bone and mineral metabolism. In: Harrison's Principles of In-ternal Medicine. Wilson JD, Braunwald E, lsselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, Root RK (Eds.), McGraw Hill, New York (1990:1888–1902.
   Google Scholar
• BARNICOT NA: The local action of the parathyroid and other tissues onbone intra cerebral grafts. j Anat. (1948) 82:233–248.
   Web of Science ®Google Scholar
• RAISZ LG: Stimulation of bone resorption by parathy-roid hormone in tissue culture. Nature (1963) 197:1015–1016.
   PubMed Web of Science ®Google Scholar
• HOLTRUP ME, KING GJ: The ultrastructure of the osteo-clast and its functional implications. Clin. Orthoip. Res. (1977) 123:177–186.
   PubMedGoogle Scholar
• FELDMAN RS, KRIEGER NS, TASHJIAN AH, Jr.: Effects of parathyroid hormone and calcitonin on osteoclast for-mation in vitro. Endocrinology (1980) 107:1137–1143.
   Google Scholar
• YAMAGUCHI DT, HALM TJ, INDA-KLEIN A, KLEEMAN CR, MUALLEM S: Parathyroid hormone-activated calcium channels man osteoblast-like clonal cell line: cAMP-de-pendent and cAMP-independent calcium channels. J. Biol. Chem. (1987) 262:7711–7721.
   PubMed Web of Science ®Google Scholar
• RODAN GA, MARTIN TJ: Role of osteoblasts in hormonal control of bone resorption: a hypothesis. Calcif Tiss. Int. (1981) 33:349–351.
   PubMed Web of Science ®Google Scholar
• MARTIN TJ, FINDLAY DM, MOSELEY JM: Peptide hor-mones acting on bone. In: Osteoporosis. Marcus R, Feldman D, Kelsey J (Eds.), Academic Press, San Diego (1996): 185–204.
   Google Scholar
• CANALIS E, CENTRELLA M, BURCH W, MCCARTHY TL: Insulin-like growth factor 1 mediates selective anabolic effects of parathyroid hormone in tissue culture. J. Clin. Invest. (1989) 83:60–65.
   PubMed Web of Science ®Google Scholar
• MUNDY GR, MARTIN TJ: The hypercalcemia of malig-nancy: pathogenesis and treatment. Metabolism (1982) 31:1247–1277.
   PubMed Web of Science ®Google Scholar
• ORLOFF JJ, WU TL, STEWART AF: Parathyroid hormone-like proteins: biochemical responses and receptor in-teractions. Endocrinol. Rev. (1989) 10:476–495.
   PubMed Web of Science ®Google Scholar
• THIEBAUD D, JANISCH S, KOELBL H eta].: Direct evidenceof a parathyroid related gradient between the mother and the newborn in humans. Bone Miner. (1993) 23:213–221.
   Google Scholar
• RIGGS BL, WAHNER HW, SEEMAN E et al.: Changes inbone mineral density of the proximal femur and spine with ageing. Differences between the post-menopausal and senile osteoporosis syndromes. J. Clin. Invest. (1982) 70:716–723.
   Google Scholar
• WASNICH RD, ROSS PD, HEILBRUN LK, VOGEL JM: Predic-tion of postmenopausal fracture risk with use of bone mineral measurements. Am. J. Obstet Gynecol. (1985) 153:745–751.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, BLACK DM, NEVITT MC: Bone density at various sites for the prediction of hip fractures. Lancet (1993) 341:72–75.
   PubMed Web of Science ®Google Scholar
• ROSS PD, WASNICH RD, VOGEL JM: Detection of prefrac-ture osteoporosis using bone mineral absorptiometry. J. Bone Miner. Res. (1988) 3:1–11.
   PubMed Web of Science ®Google Scholar
• BURROWS R: Variations produced in bones of growing rats by parathyroid extracts. Am. J. Anat. (1938) 62:237–290.
   Google Scholar
• SELYE H: On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. J. Endocrinol. (1932) 16:547–558.
   Google Scholar
• KALU DN, PENNOCK J, DOYLE FH, FOSTER GV: Parathy-roid hormone and experimental osteosclerosis. Lancet (1970) 1:1363–1366.
   PubMed Web of Science ®Google Scholar
• TAM CS, HEERSCHE JNM, MURRAY TM, PARSONS JA: Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology (1982) 110:506–512.
   PubMed Web of Science ®Google Scholar
• PODBESEK R, EDUOARD C, MEUNIER PJ eta].: Effects of two treatment regimens with synthetic human parathy-roid hormone fragment on bone formation and the tissue balance oftrabecular bone in greyhounds. Endo-crinology (1983) 112:1000–1005.
   Google Scholar
• DEMPSTER DW, COSMAN F, PARISIEN M, SHEN V, LINDSAY R: Anabolic actions of parathyroid hormone on bone.Endocr. Rev. (1993) 14:690-709. Good review of skeletal anabolic effects PTH.
   Google Scholar
• REEVE J: PTH: A future role in the management of osteoporosis? J. Bone Miner. Res. (1996) 11:440–445.
   PubMed Web of Science ®Google Scholar
• HORI M, UZAWA T, MORITA K et al.: Effect of human parathyroid hormone (PTH (1-34)) on experimental osteopenia of rats induced by ovariectomy. Bone Miner. (1988) 3:193–199.
   PubMedGoogle Scholar
• LIU CC, KALU DN: Human parathyroid hormone (1-34) prevents bone loss and augments bone formation in sexually mature ovariectomised rats. J. Bone Miner. Res. (1990) 5:973–982.
   PubMed Web of Science ®Google Scholar
• LIU CC, KALU DN, SALERNO E eta].: Pre-existing bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J. Bone Miner. Res. (1991) 6:1071–1080.
   Google Scholar
• KIMMEL DB, BOZZATO RP, KRONIS KA eta].: The effect of recombinant human (1–84) or synthetic human (1–34) parathyroid hormone on the skeleton of adult osteopenic ovariectomised rats. Endocrinology (1993) 132:1577-1583. Study demonstrating equivalence of hPTH (1–84) and hPTH (1–34).
   Google Scholar
• WRONSKI TJ, YEN CF, QI H, DANN LM: Parathyroid hormone is more effective than estrogen or bisphos-phonate for restoration of lost bone mass in ovariec-tomised rats. Endocrinology (1993) 132:823–831.
   PubMed Web of Science ®Google Scholar
• TAKANO Y, TANIZAWA T, MASHIBA T eta].: Maintaining bone mass by bisphosphonate cimadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1–34) ad-ministration in ovariectomised rats. J. Bone Miner. Res. (1996) 11:169–177.
   Google Scholar
• MA Y, JEE WS, CHEN Yet al.: Partial maintenance of extra cancellous bone mass by anti-resorptive agents after
   Google Scholar
• SHEN V, DEMPSTER DV, BIRCHMAN R, XU R, LINDSAY R:Loss of cancellous bone mass and connectivity in ovariectomised rats can be restored by combined treat-ment with parathyroid hormone and estradiol. j Clin. Invest. (1993) 91:2479–2487.
   PubMed Web of Science ®Google Scholar
• GUNNESS-HEY M, HOCK JM: Increased trabecular bonemass in rats treated with human synthetic parathyroid hormone. Metab. Bone Dis. Relat Res. (1984) 5:177–181.
   PubMedGoogle Scholar
• HOCK JM, HUMMERT JR, BOYCE RW, FONSECA J, RAISZLG: Resorption is not essential for the stimulation of bone growth by hPTH (1-34) in rats in vivo. J. Bone Aliner. Res. (1989) 4:449–458.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI HE, TANIZAWA T, HARI M, UZAWA T: Effectof intermittent administration of human parathyroid hormone (1–34) on experimental osteopenia in rats induced by ovariectomy. Cells Mater. (1991) Suppl. 1:113–117.
   Google Scholar
• WRONSKI TJ, YEN C-F: Anabolic effects of parathyroid hormone on cortical bone in ovariectomised rats. Bone (1994) 15:51-58. Demonstration of positive effect of PTH on cortical bone.
   Google Scholar
• OXLUND H, EJERSTED C, ANDEREASSEN T, TORRING 0,NILSSON MHL: Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from pe-riosteum and endosteum. Cakit. Tissue Int. (1993) 53:394–399.
   PubMed Web of Science ®Google Scholar
• MOSEKILDE C, SOGAARD CH, MCOSKER JE, WRONSKI TJ:
   Google Scholar
• •PTH has a more pronounced effect on vertebral bone mass and biome chanical competence than anti-resorp-tive agents (estrogen and bisphosphonate) - assessed in sexually mature, ovariectomised rats. Bone (1994) 15:401-408. Ability of PTH to stimulate bone biomechanical strength.
   Google Scholar
• MOSEKILDE C, DANIELSON CC, GASSER JA: The effect onvertebral bone mass and strength of long-term treat-ment with anti-resorptive agents (estrogen and calci-tonin), human parathyroid hormone (1-38), and combination therapy, assessed in aged ovariectomised rats. Endocrinology (1994) 135:2126–2134.
   Google Scholar
• SOGAARD CH, WRONSKI TJ, MCOSKER JE, MOSEKILDE L:The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomised rats is more pronounced than that of estrogen or bisphos phonate s. Endocrinology (1994) 134:650–657.
   PubMed Web of Science ®Google Scholar
• EJERSTED C, ANDREASSEN TT, OXLUND H eta].: Humanparathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in rats. J. Bone Miner. Res. (1993) 9:1097–1101.
   Google Scholar
• MOSEKILDE C, DANIELSON CC, SOGAARD CHS, MCOSKERJE, WRONSKI TJ: The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in a sexually mature, ovariectomised rat model. Bone (1995) 16:223–230.
   PubMed Web of Science ®Google Scholar
• REEVE J, WILLIAMS D, HESP R etal.: Anabolic effect of low doses of a fragment of human parathyroid hormone onthe skeleton in postmenopausal osteoporosis. Lancet (1996) 15:1035-1038. First indication of an anabolic effect of PTH in humans.
   Google Scholar
• REEVE J, MEUNIER PJ, PARSONS JA et al.: Anabolic effectof human parathyroid hormone fragment on trabecu-lar bone in involutional osteoporosis: a multicentre trial. Br. Med. J. (1980) 280:1340–1344.
   PubMed Web of Science ®Google Scholar
• SLOVIK DM, NEER RM, POTTS JT, Jr.: Short-term effectsof synthetic human parathyroid hormone (1–34) ad-ministration on bone mineral metabolism in osteoporotic patients. J. Clin. Invest. (1981) 68:1261–1271.
   Google Scholar
• SLOVIK DM, ROSENTHAL DI, DOPPELT SH et al: Restora-tion of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-di-hydroxyvitamin D. J. Bone Miner. Res (1986) 1:377–381.
   PubMed Web of Science ®Google Scholar
• REEVE J, BRADBEER JN, ARLOT M et al.: hPTH 1-34 treatment of osteoporosis with added hormone re-placement therapy: biochemical, kinetic and histologi-cal responses. Osteopor. Int (1991) 1:162–170.
   PubMedGoogle Scholar
• REEVE J, DAVIES UM, HESP R, MCNALLY E, KATZ D:Treatment of osteoporosis with human parathyroid hormone and olxervations on effect of sodium fluo-ride. Br. Med. J. (1990) 301:314–318.
   PubMed Web of Science ®Google Scholar
• HESCH R-D, BUSCH U, PROKOP M, DALLING G, RITTING-HAUS E-F: Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addi-tion of calcitonin nasal spray in osteoporotic patients. Ca/cif Tissue mt. (1989) 44:176–180.
   PubMed Web of Science ®Google Scholar
• HESCH RD, HECK J, DELLING G et al: Results of astimulatory therapy of low bone metabolism in osteoporosis with (1-38) hPTH and diphosphonate EHDP. Klin. Wochenschr. (1988) 66:976–984.
   PubMedGoogle Scholar
• HODSMAN AB, STEER BM, FRAHER LJ, PROST DJ: Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. (1991) 14:67–83.
   PubMedGoogle Scholar
• HODSMAN AB, FRAHER LJ, ADACHI JD, OSTBYE T: Cycli-cal parathyroid hormone with or without sequential calcitonin to treat osteoporosis: final results of a 2 year clinical trial. Am. Soc. Bone. Miner. Res. (1996) 11\(Suppl. 1):T622.
   Google Scholar
• LINDSAY R, COSMAN F, SHEN V, NIEVES I, DEMPSTER DW:Bone mass increments induced by PTH treatment can be maintained by estrogen. Am. Soc. Bone Miner. Res. (1995) 10\(Suppl. 1):P287.
   Google Scholar
• HODSMAN AB, FRAHER L, ADACHI J: A clinical trial ofcyclical clodronate as maintenance therapy following withdrawal of parathyroid hormone in the treatment of postmenopausal osteoporosis. Am. Soc. Bone Miner. Res. (1995) 10 (Suppl. 1):P288.
   Google Scholar
• FINKELSTEIN J, KLIBANSKI A, SCHAEFER EH et al.: Para-thyroid hormone for the prevention of bone loss in-duced by estrogen deficiency. New Eng. J. Med. (1994) 331:1618-1623. Ability of PTH to prevent bone loss in humans.
   Google Scholar
• FINKELSTEIN J, KLIBANSKI A, NEER R: Prevention of bone loss from the hip and spine with parathyroid hormone in estrogen-deficient women. Am. Soc. Bone Miner. Res. (1995) 10\(Suppl. 1):T424.
   Google Scholar
• XING XP, YAMAMOTO J, MORITA R: Effects of parathy-roid hormone (1–34) and parathyroid hormone (1–84) on the bone mineral content in rats. Am. Soc. Bone Miner. Res. (1995) 10\(Suppl. 0:5410.
   Google Scholar
• GROEN EWJ, SCHWIETERT HR, VANMARLE SP et al.: An evaluation of single dose administration of recombi-nant human parathyroid hormone (rhPTH (1–84)) in healthy post-menopausal female volunteers. Pharm. World Sci. (1995) 17 (Suppl .:D11.
   Google Scholar
• GROEN EWJ, SCHWIETERT HR, VANMARLE SP et al.: Mul-tiple dose administration of recombinant human para-thyroid hormone (rhPTH (1-84)) in healthy post-menopausal volunteers. First Cong Eur. Assoc. Clin. Pharmacol Ther. (1995):523.
   Google Scholar
• USDIN TB, GRUBER C, BONNER TJ: Identification and functional expression of a receptor selectively recog-nising parathyroid hormone, the PTH2 receptor. J. Biol. Chem. (1995) 270:15455–15458.
   PubMed Web of Science ®Google Scholar
• HOCK JM, FONSECA J, GUNNESS-HAY M, KEMP BE, MAR-TIN TJ: Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. Endocrinology (1989) 125: 2022-2027.
   Google Scholar
• HARTKE JR, LADE DA, UNDERWOOD RA eta].: Differentialeffects of PTH and PTHrP on the skeleton and calcium homeostasis in the dog. Am. Soc. Bone Miner. Res. (1996) 11 (Suppl. 1) :S448.
   Google Scholar
• WATERS RV, LIU GS, SHEA M, HAYES WC, VICKERY B: RS-66271 restores corticosteroid induced loss of bone strength. Am. Soc. Bone Miner. Res. (1996) 11 (Suppl. 0:7.
   Google Scholar
• CAULFIELD J, KIMMEL DB, WATERS RV, VICKERY BH: Bone structure and turnover following treatment of glucocor-ticoid osteopenia in rabbits with RS-66271.Am. Soc. Bone Miner. Res. (1995) 10\(Suppl. 1):P273.
   Google Scholar
• AVNUR Z, MCRAE GI, TALLENTIRE D, VICKERY BH: RS-66271 rapidly increases bone mineral density at spine, hip and forearm in ovariectomised cynomolgus ma-caques. Am. Soc. Bone Miner. Res. (1995) 10\(Suppl. 1):P271.
   Google Scholar
• VICKERY BH, AVNUR Z, CHENG Y et al.: RS-66271, a C-terminally substituted analog of human parathyroid hormone-related protein (1-34), increases trabecular and cortical bone in ovariectomised, osteopenic rats. J. Bone Miner. Res. (1996) 11:1943–1951.
   PubMed Web of Science ®Google Scholar
• YEE JP, MONROE SE, THIENE K The effects of RS-66271, a novel hPTHrP (1–34) analog, on serum and urinary markers of PTH-like activity in healthy post-meno-pausal women. Am. Soc. Bone Miner. Res. (1996) 11 (Suppl. 1):T617.
   Google Scholar